Stock listing
Lang & Schwarz:A2PQTV Dicot Pharma AB Aktie
German listing (Lang & Schwarz) of Dicot Pharma AB · home listing Stockholm:DICOT
Follow Dicot Pharma AB into a list and get an email when it puts out news.
Home listing price · OMXSTO:DICOT
0.196 SEK -0.012 (-5.7%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, OMXSTO:DICOT
- Day range
- 0.192 – 0.206 SEKNov 20, 2026
- Volume
- 9.40M sharesNov 20, 2026
- Market cap
- 680.6M SEKAt the close on Nov 20, 2026 · price × 3.47B shares outstanding
- 52-week range
- 0.175 – 0.540 SEKLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- 1.84M SEKMedian day 6.75M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Stockholm:DICOT · Home | 0.196 SEK | -0.012 (-5.7%) | 9,395,311 | 0.206 | 0.206 | 0.192 | 0.208 | Close on Nov 20, 2026 |
| Frankfurt:KN0 | €0.011 EUR | -0.001 (-9.5%) | — | €0.013 | €0.013 | €0.011 | €0.013 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OMXSTO:DICOT · SEK, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 0.196 | -0.012 | -5.7% | 0.206 | 0.206 | 0.192 | 9,395,311 | |
| 0.208 | -0.002 | -1.0% | 0.225 | 0.230 | 0.203 | 9,484,330 | |
| 0.210 | -0.004 | -1.8% | 0.212 | 0.218 | 0.206 | 4,356,737 | |
| 0.214 | -0.004 | -1.7% | 0.213 | 0.218 | 0.210 | 5,523,365 | |
| 0.218 | +0.002 | +0.8% | 0.215 | 0.218 | 0.210 | 4,109,242 | |
| 0.216 | +0.005 | +2.6% | 0.214 | 0.219 | 0.214 | 3,071,403 | |
| 0.210 | -0.001 | -0.5% | 0.220 | 0.220 | 0.210 | 3,521,441 | |
| 0.211 | -0.003 | -1.2% | 0.213 | 0.213 | 0.207 | 4,171,888 | |
| 0.214 | -0.003 | -1.4% | 0.216 | 0.219 | 0.210 | 5,588,433 | |
| 0.217 | -0.002 | -1.0% | 0.219 | 0.220 | 0.213 | 3,090,424 | |
| 0.219 | +0.002 | +1.0% | 0.217 | 0.220 | 0.214 | 1,720,411 | |
| 0.217 | -0.001 | -0.6% | 0.216 | 0.224 | 0.210 | 5,613,719 | |
| 0.218 | +0.001 | +0.4% | 0.221 | 0.229 | 0.214 | 4,161,587 | |
| 0.218 | -0.007 | -3.0% | 0.250 | 0.250 | 0.218 | 9,517,843 | |
| 0.224 | -0.001 | -0.4% | 0.219 | 0.230 | 0.210 | 3,845,364 | |
| 0.225 | 0.000 | -0.1% | 0.225 | 0.233 | 0.220 | 7,475,291 | |
| 0.226 | +0.010 | +4.6% | 0.216 | 0.231 | 0.216 | 7,648,272 | |
| 0.216 | +0.003 | +1.4% | 0.212 | 0.220 | 0.210 | 5,533,011 | |
| 0.213 | -0.001 | -0.3% | 0.213 | 0.215 | 0.209 | 2,902,970 | |
| 0.213 | -0.003 | -1.5% | 0.218 | 0.219 | 0.206 | 5,400,475 | |
| 0.216 | +0.007 | +3.1% | 0.210 | 0.218 | 0.207 | 4,679,463 | |
| 0.210 | -0.014 | -6.3% | 0.224 | 0.224 | 0.198 | 28,694,647 | |
| 0.224 | -0.013 | -5.6% | 0.230 | 0.232 | 0.221 | 11,132,955 | |
| 0.237 | -0.003 | -1.2% | 0.236 | 0.240 | 0.224 | 8,883,793 | |
| 0.240 | -0.007 | -2.8% | 0.247 | 0.247 | 0.232 | 10,025,506 | |
| 0.247 | +0.002 | +0.7% | 0.245 | 0.260 | 0.233 | 18,647,957 | |
| 0.245 | -0.003 | -1.2% | 0.248 | 0.250 | 0.239 | 7,762,771 | |
| 0.248 | -0.006 | -2.3% | 0.254 | 0.259 | 0.245 | 9,624,111 | |
| 0.254 | +0.018 | +7.8% | 0.240 | 0.258 | 0.233 | 18,235,259 | |
| 0.235 | +0.009 | +4.2% | 0.225 | 0.239 | 0.223 | 7,188,175 | |
| 0.226 | +0.004 | +1.6% | 0.222 | 0.228 | 0.220 | 3,772,041 | |
| 0.222 | +0.001 | +0.5% | 0.221 | 0.225 | 0.219 | 3,638,625 | |
| 0.221 | -0.004 | -1.6% | 0.220 | 0.224 | 0.212 | 6,505,502 | |
| 0.225 | -0.003 | -1.1% | 0.228 | 0.235 | 0.219 | 9,030,304 | |
| 0.228 | +0.007 | +3.0% | 0.223 | 0.232 | 0.223 | 2,841,577 | |
| 0.221 | -0.011 | -4.7% | 0.232 | 0.235 | 0.221 | 3,097,079 | |
| 0.232 | +0.005 | +2.3% | 0.230 | 0.240 | 0.227 | 10,137,986 | |
| 0.227 | 0.000 | -0.1% | 0.227 | 0.235 | 0.224 | 3,572,907 | |
| 0.227 | 0.000 | -0.1% | 0.229 | 0.234 | 0.223 | 4,167,847 | |
| 0.227 | +0.002 | +0.9% | 0.225 | 0.235 | 0.225 | 3,603,256 | |
| 0.225 | -0.001 | -0.4% | 0.226 | 0.228 | 0.218 | 4,495,539 | |
| 0.226 | -0.006 | -2.7% | 0.232 | 0.239 | 0.218 | 7,515,708 | |
| 0.232 | -0.004 | -1.9% | 0.235 | 0.239 | 0.230 | 2,825,017 | |
| 0.237 | +0.002 | +0.8% | 0.231 | 0.237 | 0.222 | 6,848,558 | |
| 0.235 | 0.000 | -0.2% | 0.235 | 0.238 | 0.229 | 3,590,847 | |
| 0.235 | -0.007 | -3.0% | 0.242 | 0.243 | 0.230 | 5,377,074 | |
| 0.242 | -0.006 | -2.5% | 0.248 | 0.248 | 0.237 | 6,753,879 | |
| 0.249 | +0.003 | +1.1% | 0.246 | 0.259 | 0.245 | 5,365,281 | |
| 0.246 | +0.003 | +1.3% | 0.243 | 0.254 | 0.243 | 6,744,764 | |
| 0.243 | -0.008 | -3.3% | 0.251 | 0.254 | 0.240 | 6,451,094 | |
| 0.251 | -0.002 | -0.7% | 0.269 | 0.269 | 0.240 | 20,020,236 | |
| 0.253 | 0.000 | 0.0% | 0.253 | 0.253 | 0.253 | 15,419,584 | |
| 0.253 | -0.001 | -0.6% | 0.260 | 0.267 | 0.249 | 11,270,532 | |
| 0.254 | +0.015 | +6.2% | 0.238 | 0.259 | 0.230 | 31,509,641 | |
| 0.239 | +0.011 | +4.6% | 0.227 | 0.239 | 0.224 | 11,121,386 | |
| 0.229 | +0.009 | +4.0% | 0.220 | 0.239 | 0.215 | 18,224,697 | |
| 0.220 | +0.008 | +3.8% | 0.212 | 0.224 | 0.206 | 8,665,924 | |
| 0.212 | +0.001 | +0.5% | 0.211 | 0.212 | 0.200 | 8,084,634 | |
| 0.211 | -0.004 | -1.8% | 0.215 | 0.216 | 0.205 | 8,430,890 | |
| 0.215 | +0.001 | +0.4% | 0.214 | 0.220 | 0.210 | 6,936,059 | |
| 0.214 | +0.008 | +3.9% | 0.206 | 0.215 | 0.204 | 6,038,097 | |
| 0.206 | -0.004 | -1.9% | 0.210 | 0.216 | 0.202 | 7,154,087 | |
| 0.210 | +0.001 | +0.5% | 0.209 | 0.216 | 0.198 | 10,798,547 | |
| 0.209 | -0.011 | -4.9% | 0.220 | 0.225 | 0.204 | 10,589,902 |
- Ticker
- Lang & Schwarz:A2PQTV
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Lang & Schwarz
- Currency
- EUR
What changed lately
Latest news release · Aug 19, 2026
Dicot Pharma: three abstracts on LIB-01 selected for presentation at leading sexual medicine conference
Latest news
Dicot Pharma: three abstracts on LIB-01 selected for presentation at leading sexual medicine conference
Aug 19, 2026
Closed 0.22 (+1.6%) on Aug 19, 2026
Dicot Pharma Recruits Cecilia Driving As CFO
Jul 1, 2026
Closed 0.226 (+5.3%) on Jul 2, 2026
Dicot Pharma Gets FDA Clearance To Start First Part Of Phase 2B Study With Lib-01 In U.S.
Jun 25, 2026
Closed 0.195 (-3.0%) on Jun 25, 2026
Dicot Pharma announces last day of trading in BTU and first day of trading in warrants of series TO 7
Jun 24, 2026
Closed 0.201 (-2.0%) on Jun 24, 2026
Dicot Pharma Announces Outcome In Oversubscribed Rights Issue
Jun 9, 2026
Closed 0.252 (+6.7%) on Jun 9, 2026
Dicot Pharma presents at Aktiespararnas’ event Aktiedagarna on June 9
Jun 5, 2026
Closed 0.231 (-1.7%) on Jun 5, 2026
Dicot Pharma announces preliminary outcome in oversubscribed rights issue
Jun 4, 2026
Closed 0.231 (-1.7%) on Jun 5, 2026
Dicot Pharma announces the final subscription date for units in the ongoing rights issue
May 29, 2026
Closed 0.196 (-5.3%) on May 29, 2026
DICOT: Over 80% of the rights issue is secured, ensuring funding for the planned phase 2b study
May 27, 2026
Closed 0.208 (-3.3%) on May 27, 2026
Dicot Pharma Submits IND Application To FDA
May 25, 2026
Closed 0.228 (+9.0%) on May 25, 2026
Dicot Pharma AB on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 25 in the last 12 months · 35 in all · newest Aug 19, 2026 · oldest 2024
- Decks
- 1 deck · latest Nov 3, 2024
Where Dicot Pharma AB is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Stockholm:DICOT · Home listing | Stockholm | Sweden | SEK |
| LS Exchange:A2PQTV | LS Exchange | Germany | EUR |
| Frankfurt:KN0 | Frankfurt | Germany | EUR |
| Lang & Schwarz:A2PQTV · This page | Lang & Schwarz | Germany | EUR |
| OTC:DCOIF | OTC | United States | USD |
| Stockholm:DICOTBTU | Stockholm | Sweden | SEK |
| Stuttgart:KN0 | Stuttgart | Germany | EUR |
Valuation
Price/book 3.0× against a median of 3.1×: 5th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- 455.1M SEK
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 3.0×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Dicot Pharma AB · OMXSTO:DICOT | US$66.64M | US$44.56M | n/a | n/a | n/a | 3.0× | n/a | 0.0× | n/a |
| MAIA Biotechnology, Inc. · AMEX:MAIA | US$68.54M | US$68.54M | n/a | n/a | n/a | 4.7× | n/a | 0.0× | 1.62 |
| ABIONYX Pharma SA · EURONEXT:ABNX | US$68.36M | US$55.53M | n/a | 12.4× | n/a | 4.0× | −136.6% | 1.0× | n/a |
| Cingulate Inc. · NASDAQ:CING | US$67.48M | US$1.21B | n/a | n/a | n/a | 3.3× | n/a | 56.0× | 1.41 |
| Energenesis Biomedical Co., Ltd. · TWSE:6657 | US$67.20M | US$47.01M | n/a | 203× | n/a | 3.1× | n/a | 0.0× | n/a |
| MediciNova, Inc. · NASDAQ:MNOV | US$67.11M | US$38.45M | n/a | 41.1× | n/a | 1.6× | n/a | 0.0× | 0.56 |
| Cardiff Oncology, Inc. · NASDAQ:CRDF | US$66.34M | US$32.82M | n/a | 58.7× | n/a | 2.4× | n/a | 0.0× | 1.32 |
| Polaryx Therapeutics, Inc. · NASDAQ:PLYX | US$66.30M | US$57.86M | n/a | n/a | n/a | 8.7× | n/a | 0.0× | 1.66 |
| PMV Pharmaceuticals, Inc. · NASDAQ:PMVP | US$66.17M | −US$36.25M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.43 |
| Gossamer Bio, Inc. · NASDAQ:GOSS | US$65.57M | US$55.23M | n/a | 0.7× | n/a | n/a | −159.5% | n/a | 1.56 |
| Tenaya Therapeutics, Inc. · NASDAQ:TNYA | US$65.32M | US$1.38M | n/a | 0.5× | n/a | 1.2× | n/a | 0.1× | 2.42 |
| Median of the others | US$66.73M | US$51.12M | 26.8× | 3.1× | −148.0% | 0.0× | 1.50 |
Team and board
Officers
| Officer | Role |
|---|---|
| Elin Trampe | CEO |
Board
| Director | Role |
|---|---|
| Eva Sjökvist Saers | Chairman |
| Carl Leijonhufvud | Board Member |
| Göran Beijer | Board Member |
| Tore Robertsson | Board Member |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (2024) | Technical | 5 slides | Nov 3, 2024 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Rights offering of units of shares and warrants of series TO 7 Update: rights offering | Jun 24, 2026 | |
| Warrant exercise of shares via warrants series TO 6 Closed: SEK 43.8M raised · SEK 0.19 a share | Apr 2, 2025 | US$4.41M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in SEK
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling, general and administrative | 23.9M | ||||
| Operating income | -82.6M | -59.3M | -45.0M | -31.8M | -27.3M |
| Depreciation and amortization | 0 | 6.00K | 8.00K | 7.55K | 7.55K |
| EBITDA | -82.6M | -59.3M | -45.0M | -31.8M | -27.2M |
| Interest expense | 6.00K | 10.0K | 66.0K | 33.1K | 3.87K |
| Income before tax | -80.2M | -57.7M | -44.2M | -31.8M | -27.2M |
| Net income | -80.2M | -57.7M | -44.2M | -31.8M | -27.2M |
| Earnings per share, basic | -0.04 | -0.03 | -0.04 | -0.10 | -0.13 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | 69.2M | 113.4M | 47.3M | 9.38M | 30.3M |
| Receivables | 8.30M | 4.80M | |||
| Inventory | 8.00M | 5.38M | 3.40M | 1.49M | 0 |
| Current assets | 85.5M | 123.6M | 53.5M | 12.4M | 31.7M |
| Total assets | 85.5M | 123.6M | 53.6M | 12.4M | 31.8M |
| Accounts payable | 6.12M | 6.84M | 4.54M | 3.42M | 2.58M |
| Current liabilities | 12.1M | 12.0M | 9.16M | 7.01M | 3.42M |
| Total liabilities | 12.1M | 12.0M | 9.16M | 7.01M | 3.42M |
| Shareholders' equity | 73.4M | 111.7M | 44.4M | 5.36M | 28.4M |
| Shares outstanding | 2.26B | 2.00B | 1.25B | 315.9M | 211.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash from operations | -85.9M | -58.9M | -45.2M | -29.7M | -25.9M |
| Capital spending | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | -85.9M | -58.9M | -45.2M | -29.7M | -25.9M |
| Change in cash | -44.2M | 66.1M | 38.0M | -21.0M | 10.0M |
Cap table
Built by 6ix from Dicot Pharma AB’s releases · as of Apr 2, 2025
- Common shares
- 3,468,689,230
- Fully diluted
- 3,468,689,230
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 3,468,689,230 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 3,468,689,230 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Elin Trampe | CEO · Since at least Aug 19, 2026 |
| Eva Sjökvist Saers | Chairman · Since at least May 6, 2026 |
Log in to ask 6ix AI your own questions about Dicot Pharma AB.